AlphaStocks

ABT vs AZN

As of Sep 20, 2026, Abbott Laboratories (ABT) scores 5.3/10 and Astrazeneca (AZN) 5.0/10 on AlphaStocks' five-model composite, so ABT scores higher. ABT trades 4% below its model fair value; AZN trades 14% below its model fair value.

ABT

ABBOTT LABORATORIES

5.3

Consider Buy

$102.57

AZN

ASTRAZENECA PLC

5.0

Consider Buy

$166.29

ABT vs AZN: Which is the Better Investment?

ABBOTT LABORATORIES (ABT) scores 5.3/10 while ASTRAZENECA PLC (AZN) scores 5.0/10 on AlphaStocks' composite model. ABBOTT LABORATORIES has the higher composite rating of Consider Buy. On a P/E basis, ASTRAZENECA PLC trades at 25.4x, making it the more attractively priced of the two. ASTRAZENECA PLC trades further below its estimated fair value.

This comparison is algorithmically generated and is not financial advice.

MetricABTAZN
Scores & Fundamentals
Composite Score5.3/105.0/10
RatingConsider BuyConsider Buy
Price$102.57$166.29
P/E Ratio27.525.4
ROE12.7%21.9%
Market Cap$179B$260B
Fair Value$107.10$192.63
Dividend Yield2.5%1.9%
Sector Rank#85 of 168#111 of 168
Model Verdicts
PiotroskiAttractiveStrong
BuffettStrongStrong
GrahamNeutralCaution
LynchNeutralNeutral
GreenblattAttractiveNeutral
View full ABTanalysis →View full AZNanalysis →

Related comparisons

Compare any two stocks →

ABT vs AZN: Which Stock Scores Higher?

ABBOTT LABORATORIES (ABT) and ASTRAZENECA PLC (AZN) are both in the Health Care sector. ABT currently leads with a composite score of 5.3/10 (Consider Buy) compared to AZN's 5.0/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer